MedWatch

Lundbeck gets FDA-accept and million-dollar milestone payment

The FDA has accepted the Danish company’s registration application for its anti-depressant vortioxetin. The accept also triggers a milestone payment from a Japanese business partner.

Foto: Lundbeck/PR

Last week FDA accepted Lundbeck’s registration application for the anti-depressant vortioxetin, and Brintellix was announced as the suggested global brand.

The news also triggered a milestone payment of 285 million kroner (50 million USD) from the company’s Japanese partner Takeda. But none of these events will have any impact on expectations for 2012, the company informed Wednesday.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier